Financial/nonfinancial disclosures: The authors have reported to CHEST the following conflicts of interest: Within the past 5 years, Dr Boulet served on advisory boards for AstraZeneca, Altana, GlaxoSmithKline, Merck Frosst, and Novartis. Dr Boulet received lecture fees from 3M, Altana, AstraZeneca, GlaxoSmithKline, Merck Frosst, and Novartis. Dr Boulet received sponsorships for investigator-generated research from AstraZeneca, GlaxoSmithKline, Merck Frosst, and Schering. Dr Boulet received research funding for participating in multicenter studies from 3M, Altana, AsthmaTx, AstraZeneca, Boehringer-Ingelheim, Dynavax, Genentech, GlaxoSmithKline, IVAX, MedImmune, Merck Frosst, Novartis, Roche, Schering, Topigen, and Wyeth. Dr Boulet received support for the production of educational materials from AstraZeneca, GlaxoSmithKline, and Merck Frosst. Dr Boulet served as a governmental adviser for the Conseil du Médicament du Québec, as a member of the Quebec Workmen Compensation Board Respiratory Committee Organisational, as chair of the Canadian Thoracic Society Guidelines Dissemination and Implementation Committee, and as coleader of the Therapeutics Theme of the Canadian AllerGen Network of Centers of Excellence. Dr Boulet held the Laval University Chair on Knowledge Transfer, Prevention and Education in Respiratory and Cardiovascular Health. Dr Boulet was a member of the Asthma Committee of the World Allergy Organization. Dr McIvor received honoraria for attending advisory board meetings and providing continuing medical education activities for pharmaceutical companies involved in the management of asthma, including AstraZeneca, GlaxoSmithKlein, Merck, and Novartis. Dr Hernandez served on advisory boards and provided speaking activities (continuing health education) from 2006 to 2009 for Actelion, Altana, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Nycomed, and Pfizer. Dr Field received pharmaceutical company grant monies from Novartis and Boehringer Ingelheim. Dr Field served on advisory boards for Nycomed, GlaxoSmithKline, and AstraZeneca. Dr Field participated in speaking activities for GlaxoSmithKline, Nycomed, and Abbott. Dr Aaron served on advisory boards for GlaxoSmithKline, Boerhinger-Ingelheim, and Astra-Zeneca. Dr Aaron received about $10,000 for these activities in the past 2 years. Mr Doucette, Ms Vandemheen, and Drs Parkhale, FitzGerald, Lemiere, Sharma, Alvarez, and Dales have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.